NASDAQ
INmune Bio, Inc. (INMB) has a free cash flow growth of 7.05% as of Friday, May 29, 2026. This represents a 66.80% decrease compared to its 12-month average of 21.23%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.